Johnson & Johnson asked rival Covid-19 vaccine makers to study blood clotting risks: report
- AstraZeneca – which had been buffeted by blood clotting concerns – agreed, while Pfizer and Moderna declined, the WSJ reported
- US officials had on Tuesday recommended pausing use of Johnson & Johnson’s vaccine to review cases of blood clots
AstraZeneca, which had been buffeted by similar blood clotting concerns for weeks, agreed, while Pfizer and Moderna executive declined, saying their vaccines appeared safe, the report said.
Last week, European regulators said they were reviewing rare blood clots in four recipients of the J&J shot in the United States, after which, the Journal report said, the company began to reach out to other vaccine makers.
06:18
SCMP Explains: What’s in a Covid-19 vaccine?
Pfizer and Moderna also objected because they did not see the need to duplicate the efforts of agencies and companies that were already looking for blood clot cases and investigating the cause, according to the report.
The specific adverse event has not been reported by those who received the Pfizer and Moderna vaccines, the companies had said.
J&J, AstraZeneca, Pfizer and Moderna were not immediately available for comments on the report.
